Search results
Showing 8116 to 8130 of 8239 results
NICE is getting ready for the end of the transition period after Brexit
NICE has a key role in ensuring the UK remains a destination of choice for the life sciences sector.
NICE outlines steps needed to put ME/CFS guideline into practice
NICE has today, (Thursday, 12 May 2022) published its implementation statement for its recent guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS)
Changes to the way medicines and other health technologies are evaluated by NICE have now been incorporated into NICE’s new combined methods and processes manual and topic selection manual published today (31 January 2022).
One year on from the first national lockdown, NICE has today (23 March) published a single guideline for the management of COVID-19 in children and adults.
NICE publishes updated clinical guideline on the diagnosis and management of atrial fibrillation
NICE has today (27 April 2021) published its updated guideline on the diagnosis and management of atrial fibrillation (AF).
NICE reaches important milestone in the UK's efforts to tackle antimicrobial resistance.
Two new antimicrobial drugs are close to becoming the first to be made available as part of the UK’s innovative subscription-style payment model.
Ovarian cancer patients to have NICE-approved drug combination option on Cancer Drugs Fund
A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer will now be available on the Cancer Drugs Fund (CDF), following its approval by NICE in draft guidance published today.
Over 700 people a year could benefit from a new lung cancer drug
An innovative and potentially life-extending drug for treating people with a specific gene mutation of advanced non-small-cell lung cancer (NSCLC) has been recommended by NICE and will be available to patients from today (Thursday, 14 April).
Patients with rare blood disorders to receive new treatment option, says NICE
In final guidance published today (20 May 2021), NICE has recommended ravulizumab (Ultomiris, Alexion Pharmaceuticals) as a treatment for paroxysmal nocturnal haemoglobinuria (PNH). Draft guidance published 19 May 2021 also recommends the treatment for atypical haemolytic uraemic syndrome (aHUS).
Avelumab not recommended as a maintenance treatment of urothelial cancer
NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of urothelial cancer after platinum-based chemotherapy.
More evidence needed to recommend Type 2 diabetes treatment tirzepatide
More evidence is needed on the clinical and cost-effectiveness of a new treatment option for people with type 2 diabetes before it could be recommended for NHS use
New treatment option for adults with obesity and non-diabetic hyperglycaemia
All eligibility criteria must be met for Liraglutide to be offered.
Women should be offered induced labour earlier than previously advised
Induced labour should be offered earlier than previously advised to make birth safer for women and their babies, according to draft guidelines published by NICE today (25 May 2021). The updated recommendations strengthen previous advice in the light of new evidence on induction timings.
More people could be treated out of hospital in the NHS's new respiratory hubs and virtual wards
Consultation launched on draft guidance for the assessment and management of acute respiratory infections in people over 16
Around 100,000 fewer colonoscopies expected to take place each year
Tens of thousands of people a year could be spared the need for a colonoscopy following new guidance from NICE.